Ari Melnick

Dr. Ari Matthew Melnick has been graduated in Medicine from the University of Buenos Aires in 1990 and has worked at prestigious institutions such as the Mount Sinai School of Medicine and the Weill Cornell Cancer Center (New York, USA), where he has led the “Hematologic Malignancies Program” and been "Gebroe Family" Professor since 2013. Internationally recognised in the field of haematological diseases and cancer epigenetics, Dr Melnick was among the first to develop rationally designed transcription factor inhibitors and conduct large-scale epigenomic studies in humans. His research demonstrated that aberrant epigenetic programming is a hallmark of cancer, and that epigenetic diversity is a fundamental determinant of tumour fitness and unfavourable clinical outcomes. He has authored more than 360 manuscripts, and therapeutic approaches he developed and identified have been approved by the FDA or moved to phase III clinical trials. For this he has been awarded the American Society of Hematology Ernest Beutler Prize in Translational Research. Dr Melnick serves on the Board of Directors of the Leukemia and Lymphoma Society and the Lymphoma Research Foundation. Dr. Melnick is currently Director of the Josep Carreras Leukaemia Research Institute, an international reference center dedicated to advancing innovation in the epidemiological, clinical, translational, and basic research of leukaemia and related hematologic diseases. He leads strategic programmes to accelerate the development of personalised therapies, strengthen translational research and promote equity and international collaboration in the fight against haematological cancers.